Long non-coding RNA CCRR controls cardiac conduction via regulating intercellular coupling

Yong Zhang¹, Lihua Sun¹, Lina Xuan¹, Zhenwei Pan¹, Xueling Hu¹, Hongyu Liu², Yunlong Bai¹, Lei Jiao¹, Zhange Li¹, Lina Cui¹, Xiaoxue Wang¹, Siqi Wang¹, Tingting Yu¹, Bingbing Feng¹, Ying Guo¹, Zonghong Liu², Weixin Meng², Hequn Ren¹, Ji Yuan Zhu³, Xuyun Zhao¹, Chao Yang¹, Ying Zhang¹, Chaoqian Xu⁴, Zhiguo Wang¹, Yanjie Lu¹, Hongli Shan¹ & Baofeng Yang¹,⁵

Long non-coding RNAs (lncRNAs) have emerged as a new class of gene expression regulators playing key roles in many biological and pathophysiological processes. Here, we identify cardiac conduction regulatory RNA (CCRR) as an antiarrhythmic lncRNA. CCRR is downregulated in a mouse model of heart failure (HF) and in patients with HF, and this downregulation slows cardiac conduction and enhances arrhythmogenicity. Moreover, CCRR silencing induces arrhythmias in healthy mice. CCRR overexpression eliminates these detrimental alterations. HF or CCRR knockdown causes destruction of intercalated discs and gap junctions to slow longitudinal cardiac conduction. CCRR overexpression improves cardiac conduction by blocking endocytic trafficking of connexin43 (Cx43) to prevent its degradation via binding to Cx43-interacting protein CIP85, whereas CCRR silence does the opposite. We identified the functional domain of CCRR, which can reproduce the functional roles and pertinent molecular events of full-length CCRR. Our study suggests CCRR replacement a potential therapeutic approach for pathological arrhythmias.
In order for heart to maintain efficient ejection of blood, cardiac muscles (cardiomyocytes) operate as a single functional syncytium, that is, they contract in unison. This is because individual cardiac muscle cells are connected by the highly organized intercalated discs where gap junctions are concentrated allowing for well-orchestrated spatial propagation of action potentials through tight cardiomyocyte–cardiomyocyte coupling. Intercellular conduction of excitation through gap junctions, or more specifically gap junction channel proteins, forms electrical coupling that is essential for the functional myocardial syncytium thereby the normal impulse propagation throughout the heart. Impaired electrical coupling promotes arrhythmogenicity and consequently contractile dysfunction. In myocardium, gap junctions exist as plaques of hexameric arrays containing hundreds to thousands of connexins, particularly connexin 43 (Cx43), the pore forming subunits of gap junction channels that create a conduit connecting the cytoplasm between cells. A hallmark of the electrical disorders with regard to impulse conduction in heart failure (HF) is the electrical uncoupling due to diminished presence of Cx43 in gap junctions, resulting in slowed conduction velocity (CV) and dispersed impulse propagation, leading to an increased risk of re-entrant excitation, predisposing to cardiac arrhythmia and even sudden cardiac death.

Recently, long noncoding RNAs (lncRNAs) have emerged as a new player of gene expression regulation and coordination. These newly recognized regulatory molecules are mRNA-like transcripts ranging from 200 nt to 100 kb in length, featured by lack of protein-coding activity, yet can participate in many fundamental biological processes and pathophysiological events. In particular, the demonstration of their roles in human cancer development and neuronal disease has garnered tremendous research interest in their possible roles in cardiovascular disease. While a number of lncRNAs have been documented to participate in the development of HF, the possible role of these noncoding RNAs in shaping cardiac electrophysiology has not been thus far revealed.

In our pilot studies, we analyzed the microarray profiling of lncRNAs expression in a mouse model of pressure-overload HF characterized by electrophysiological disturbance with slowed cardiac conduction and increased propensity of ventricular arrhythmias. A multitude of lncRNAs and mRNAs are differentially expressed to significant levels. Bioinformatics analyses (GO analysis, pathway analysis, and lncRNAs-mRNAs co-expression network analysis) enabled us to identify a subset of lncRNAs of high profiles linking to HF. Among these, AK045950 stands out as a unique lncRNA that has the potential to impose impacts on the development of HF, and the associated electrical remodeling process. We, therefore, conducted the present study to explore the role of this lncRNA in regulating cardiac conduction and the associated arrhythmogenesis and to decipher the underlying cellular and molecular mechanisms. Since AK045950 is the first lncRNA identified to have the ability to control cardiac conduction, we named it CCRR. We report here that CCRR is downregulated in a mouse model of HF and in patients with HF, and this downregulation slows cardiac conduction and enhances arrhythmogenicity in HF. Moreover, CCRR silencing induces arrhythmias in healthy mice. CCRR overexpression eliminates these detrimental alterations. HF or CCRR knockdown causes destruction of intercalated discs and gap junctions to slow longitudinal cardiac conduction. CCRR overexpression improves cardiac conduction by blocking endocytic trafficking of Cx43 to prevent its degradation via binding to Cx43-interacting protein CIP85, whereas CCRR silence does the opposite. We also identified the functional domain of CCRR, which reproduces the functional roles and molecular events of the full-length CCRR. We conclude that CCRR is an antiarrhythmic lncRNA that acts by maintaining functional myocardial syncytium and its downregulation serves as a mechanism for the electrical disturbances and contractile dysfunction typically found in HF. Hence, CCRR replacement might be considered a prospective therapeutic strategy for arrhythmias under pathological conditions of the heart.

Results
Deregulation of CCRR slows cardiac conduction. Expression of CCRR was found robustly downregulated (~55%) in the myocardium of HF mice (Fig. 1a). Notably, the human homolog to CCRR was also enormously reduced in RNA samples from individuals with HF compared with healthy subjects (Fig. 1b; see Supplementary Table 1 for patient information, and Supplementary Figure 1 for the conserved sequence motif between mouse and human). The results generated by fluorescence in situ hybridization (FISH) experiments (Fig. 1c) and by Northern blot analysis (Fig. 1d) confirmed the quantitative polymerase chain reaction (qPCR) data, uncovering ~75% decrease in CCRR level in HF.

To investigate whether downregulation of CCRR has protective or detrimental consequences, we assessed the effects of CCRR on cardiac conduction and the associated arrhythmogenicity and cardiac contractile function in HF mice with both gain- and loss-of-function approaches. The results acquired using the optical mapping with voltage-sensitive dyes showed that the CV between the apex and the base for longitudinal propagation was significantly slowed in HF hearts (Fig. 2a). Similar results showing deceleration of conduction in HF was also obtained by analysis of surface ECG recordings in Langendorff-perfused hearts (Supplementary Figure 2a, b). Consistently, the generation of arrhythmias in response to programmed left ventricular tachypacing was significantly facilitated, as indicated by the increase in the incidence of ventricular tachycardia (VT) and prolongation of VT duration in HF mice (Fig. 2b). Meanwhile, cardiac contractile function was also impaired, as reflected by the decreased ejection fraction (EF), and fractional shortening (FS) (Supplementary Figure 3), as well as the decreased left ventricular wall thickness, indicating the state of HF (Supplementary Table 2 for echocardiographic characterization of HF phenotypes). Strikingly, all these deleterious alterations were significantly mitigated in HF mice pretreated with the lentivirus carrying the CCRR gene (Lv-CCRR) for overexpression (Fig. 2a, b; Supplementary Figure 3a; Supplementary Table 3). Intracavity administration of Lv-CCRR nearly abolished the electrical disturbances: acceleration of cardiac conduction and suppression of VT. The negative control lentivirus (Lv-NC) failed to elicit these beneficial effects. The efficiency of lentivirus infection was confirmed by the robust overexpression of CCRR in the myocardium (Supplementary Figures 4 and 5).

We reasoned that if downregulation of CCRR indeed contributes to the observed pathophysiological processes in our model, then artificial knockdown of this lncRNA in otherwise healthy animals should be able to reproduce the electrophysiological and contractile phenotypes of HF. Our experiments on mice that received the lentivirus containing CCRR-specific siRNA (Lv-siCCRR) via heart cavity injection after clipping the aorta indeed generated the evidence in support of this thought (Supplementary Table 4). As illustrated in Fig. 2c, d, CCRR knockdown by Lv-siCCRR decelerated cardiac conduction (also see Supplementary Figure 2c), and increased the likelihood of arrhythmia induction in normal mice. Consequently, Lv-siCCRR impaired cardiac contractile function (Supplementary Figure 3b). The effectiveness of the siRNA to knockdown endogenous CCRR was verified under both in vivo and in vitro conditions.
In all situations, the negative control siRNA (Lv-siNC) failed to produce any meaningful effects. These data suggest that CCRR is an antiarrhythmic lncRNA that acts by maintaining normal cardiac conduction and downregulation of CCRR is sufficient to cause conduction slowing leading to enhanced propensity of arrhythmias, which may account at least partly for the electrical disorders in HF.

Cellular and subcellular mechanisms for the action of CCRR. To elucidate the possible cellular and subcellular mechanisms for the antiarrhythmic properties of CCRR, we performed electron microscopic examinations on the changes of myocardial microstructure induced by HF or by Lv-CCRR or Lv-siCCRR. As shown in Fig. 3a, HF caused significant mitochondria swelling and gap junction rupturing in mice (upper left and middle panels) and patients (right panels). As anticipated, Lv-CCRR largely mitigated the adverse alterations of mitochondria and gap junction in HF mice (Fig. 3a, lower left). These detrimental alterations are consistent with the observed slowing of cardiac conduction and also indicate the possibility of uncoupling of intercellular propagation of cardiac excitations as a mechanism for the conduction slowing and enhanced arrhythmogenesis17–20.

The results presented above strongly suggested that the loss of gap junction integrity contributes to the deleterious changes of cardiac electrical and contractile function as a subcellular mechanism in our HF model. We then went on to investigate the changes of the protein level of Cx43 and CIP85 (Cx43-interacting protein of 85 kDa)21–23 in the cytoplasmic membrane.
As shown in Fig. 3b, the protein level of Cx43 was remarkably decreased in the plasma membrane but significantly increased in the cytoplasm resulted in reduction of total Cx43 protein level in HF mice relative to the Sham-Control animals (also see Supplementary Figure 6a). Similar pattern of changes of CIP85 was observed, with an exception that the total protein level of CIP85 remained unaltered in HF (Supplementary Figure 6b).

Notably, Lv-CCRR effectively corrected these HF-induced abnormal changes (Fig. 3b).

On the other hand, knockdown of endogenous CCRR by Lv-siCCRR simulated the HF-induced abnormal changes of intercalated discs and gap junctions in otherwise normal mice.
interacting protein that regulates the endocytic traffic (Fig. 5a) and patients (right panels), and the effects of CCRR overexpression (Fig. 1c). It has been documented that CIP85 regulates the localization of Cx43 as indicated by the diminished density of fluorescence signals at intercalated discs of HF hearts of both mice (Fig. 5a) and humans (Fig. 5b) or in the mouse hearts pretreated with Lv-siCCRR, and conversely increased expression of Cx43 when treated with Lv-CCRR (Fig. 5a).

The effects of CCRR on CIP85 and Cx43 were reproduced in cultured neonatal mouse ventricular myocytes (NMVMs). As shown in Supplementary Figure 7, CCRR overexpression increased the presence of Cx43 in the cytoplasmic membrane, whereas CCRR knockdown decreased it. The relationship between CIP85 and Cx43 was also verified by Western blot and immunocytostaining analyses (Supplementary Figure 8). Transfection of CIP85 siRNA (siCIP85) elevated the protein level of Cx43 while silencing CIP85.

We then further confirmed the role of CCRR in regulating intercellular communications (presumably through gap junction channels) using a diffusible dye (Lucifer yellow) in adult human ventricular cardiomyocyte AC16 cells (Fig. 6). Lv-CCRR significantly increased, whereas Lv-siCCRR nearly completely blocked, the diffusion of Lucifer yellow among AC16 cells. The results provided another line of evidence for the critical role of CCRR in maintaining overall cardiac conduction.

Cardiac conduction is determined by both intracellular conduction and intercellular propagation of excitation waves. While Cx43 is responsible for the latter, sodium channel determinates intracellular CV. We thus also assessed the effects of CCRR on Nav1.5, the primary α-subunit of cardiac sodium channels in HF mice. Our results demonstrated that Nav1.5 protein level was upregulated in the healthy mouse pretreated with Lv-siCCRR to knockdown endogenous CCRR, but downregulated when treated with Lv-CCRR for CCRR overexpression (Supplementary Figure 9). These results indicated possible acceleration of intracellular conduction, presumably as a compensatory mechanism for the loss of intercellular conduction and excluded Nav1.5 as a mechanistic link to the observed conduction disturbance in our model.

**Molecular mechanisms for the regulation of Cx43 by CCRR.**
We then took a further step to decipher how CCRR regulates Cx43 expression in the membrane. Our data from fluorescence in situ hybridization indicated that the cytoplasm is the primary workspace for CCRR as it is primarily localized in the cytoplasm (Fig. 1c). It has been documented that CIP85 regulates the endocytic trafficking of Cx43 from the plasma membrane to induce its degradation by the lysosome-mediated mechanism.** Thus, there is a possibility for CCRR to bind CIP85 to interfere the CIP85:Cx43 interactions. This is indeed supported by our theoretical analysis of RNA–protein binding using the RNA–protein interaction prediction (RPSeq) database,
which revealed a high probability of CCRR:CIP85 interaction (Supplementary Figure 10). To experimentally verify this issue, we first carried out RNA-binding protein immunoprecipitation (RIP) analysis to see if CCRR could bind CIP85. The results depicted in Fig. 7a clearly indicate the presence of such an interaction: immunoprecipitation (IP) of CIP85 specifically retrieved a robust amount of CCRR, and conversely RNA pull-down of CCRR dragged down an impressive quantity of CIP85, with an unrelated lncRNA ZFAS1 showing the negative result.

We next assessed the alterations of the endogenous CIP85:Cx43 interactions by co-immunoprecipitation (Co-IP). As exhibited in Fig. 7b, the anti-CIP85 antibody identified similar alterations of Cx43 and CIP85 levels in normal hearts as those seen above with HF hearts. Cx43 was decreased in the membrane fraction, but increased in the cytoplasm, with a net reduction of total protein levels. $P < 0.05$, $**P < 0.01$, $***P < 0.001$ Lv-siCCRR vs. Sham; $n = 6$ mice for each group. CIP85 showed similar changes but with the total protein level unaffected. $P < 0.05$, $**P < 0.01$ Lv-siCCRR vs. Sham; $n = 5$ heart samples of membrane fraction for each group, $n = 6$ for cytoplasmic fraction, and $n = 6$ for total protein. (Mean ± SEM; ANOVA followed by Dunnett’s test for multiple group comparisons, and Student t test for two group comparisons)

molecular mechanisms for the actions of CCRR, we investigated the functional role of a CCRR fragment (290 nts) encompassing the predicted binding site (Supplementary Figure 10c) by the following steps. First, we verified the ability of this fragment (for convenience, we named it FD for functional domain) to bind CIP85 using RIP and pulldown methods. As depicted in Fig. 7c, CIP85 antibody dragged down significant amount of FD. On the other hand, the CIP85 protein pulled down by FD after infection of mouse heart with a lentiviral vector carrying FD (Lv-FD) was significantly increased relative to that with the empty viral vector or with a lentiviral vector carrying a negative control sequence (Fig. 7d).

While the above results indicate that FD is sufficient to bind CIP85, we wanted to know if this fragment could reproduce the effects of the full-length CCRR on cardiac conduction. To this end, we looked the changes of cardiac CV and arrhythmias in a mouse model of acute myocardial infarction (MI) after infection with Lv-FD. The results consistently showed that FD, similar to

Fig. 4 CCRR knockdown causes destruction of intercalated discs and gap junction in healthy mice. a Representative images of electron microscopy (30,000× magnification) showing the effects of knockdown of endogenous CCRR by Lv-siCCRR on the microstructure of left ventricular cardiac muscles in healthy mice. Note the profound derangement and loss of intercalated discs in the hearts pretreated with Lv-siCCRR (dark arrows), resembling those noted in HF heart, which was not observed with Lv-siNC and Sham-Control (subjected to the surgical procedures but without lentivirus injection). Similar results were observed in another three independent experiments. b Effects of CCRR knockdown by Lv-siCCRR on the protein levels of Cx43 (left panel) and CIP85 (right panel) in healthy mice, with comparisons between the membrane and cytoplasm fractions. Lv-siCCRR elicited similar alterations of Cx43 and CIP85 levels in normal hearts as those seen above with HF hearts. Cx43 was decreased in the membrane fraction, but increased in the cytoplasm, with a net reduction of total protein levels. $P < 0.05$, $**P < 0.01$, $***P < 0.001$ Lv-siCCRR vs. Sham; $n = 6$ mice for each group. CIP85 showed similar changes but with the total protein level unaffected. $P < 0.05$, $**P < 0.01$ Lv-siCCRR vs. Sham; $n = 5$ heart samples of membrane fraction for each group, $n = 6$ for cytoplasmic fraction, and $n = 6$ for total protein. (Mean ± SEM; ANOVA followed by Dunnett’s test for multiple group comparisons, and Student t test for two group comparisons)
CCRR, rescued the delay of cardiac conduction induced by MI and suppressed the ischemic arrhythmias (Supplementary Figure 11).

Moreover, electron microscopic examination displayed that FD relieved the destruction of gap junctions induced by MI (Fig. 8a). Furthermore, while MI caused a significant decrease in Cx43 total protein level, FD recovered such a deleterious change (Fig. 8b). As a comparison, the negative construct did not elicit any appreciable beneficial effects.

As a more straightforward evidence for the role of FD on cardiac conduction, transfection of a plasmid containing FD (pFD) significantly increased the diffusion of Lucifer yellow between adult human ventricular cardiomyocyte AC16 cells (Fig. 9a), consistent with the effect of the full-length CCRR (Fig. 6). In all cases, the mutation of the nucleotides responsible for binding with CIP85 in FD (pFD-Mut; Supplementary Figure 10c) rendered a loss-of-function in regulating intercellular communications, further indicating the key role of binding of FD or CCRR to CIP85 to improve gap junction in maintaining and accelerating cardiac conduction.

To verify that changes of CCRR or FD level could indeed interfere the interaction between Cx43 and CIP85, we looked at the effects of FD overexpression on the Cx43 level pulled down by CIP85 using Co-IP analysis. As illustrated in Fig. 9b, in cultured NMVMs transfected with the pFD for overexpression, the protein level of Cx43 co-immunoprecipitated by CIP85 antibody was significantly reduced. These data provided a line of evidence that the FD of CCRR binds to CIP85 and subsequently weakens the interaction between Cx43 and CIP85.

Since CIP85 is known to induce the endocytic trafficking of Cx43 for degradation by the lysosome-mediated mechanism\(^21\text{-}^23\), we decided to investigate if functional inhibition of CIP85 binding by FD of CCRR could reduce Cx43 degradation in lysosomes. For this purpose, we conducted immunocytostaining of Cx43 and Lamp1 (the biomarker for lysosome). As illustrated in Fig. 9c, Cx43 was found localized primarily to the plasma membrane and lysosomes in the cytoplasm, and under control conditions there was only a small amount of Cx43 in the lysosomes as indicated the low level of overlapping staining between Cx43 and Lamp1. Strikingly, either pCCRR or pFD wiped out the overlapping staining indicating the decreased recruitment of Cx43 into lysosomes for degradation, and simultaneously enhanced the Cx43 staining to the cytoplasmic membrane indicating the increased presence of Cx43 in the plasma membrane. In sharp contrast, siCCRR significantly increased the level of overlapping staining between Cx43 and Lamp1, whereas pCCRR-

---

**Fig. 5** Effects of CCRR on the gap junction distribution of Cx43 and CIP85. **a** Immunostaining of cardiac slices showing the co-localization (yellow) of CIP85 (red) and Cx43 (green) proteins at the intercalated discs in healthy hearts (upper panel), and the effects of CCRR on the gap junction distribution of these proteins (600× magnification, lower panel). Knockdown of endogenous CCRR by Lv-siCCRR drastically diminished the presence of Cx43 (stained in green) in the intercalated discs in healthy mouse hearts, resembling the changes caused by HF. In contrast, CCRR overexpression by Lv-CCRR normalized the HF-induced expression repression of Cx43. DAPI (blue) was used to stain nuclei and α-actinin (red) to identify the cell contour. Similar results were observed in another three separate experiments. **b** Immunostaining of cardiac slices showing the co-localization of CIP85 (stained in red) and Cx43 (green) proteins at the intercalated discs in healthy control subjects (600× magnification). Cx43 in the intercalated discs in HF patient significantly diminished compared with healthy control subjects. DAPI (blue) was used to stain nuclei and α-actinin (red) to identify the cell contour. Similar results were observed in another two separate experiments.
NC and pFD-Mut did not cause any significant alterations relative to control.

Discussion
Collectively, we made a number of novel findings in the present study. (1) CCRR is abnormally downregulated in a mouse model of HF, which was accompanied by cardiac conduction slowing and contractile dysfunction. (2) Downregulation of CCRR alone is sufficient to induce electrophysiological disturbances and syncytium disruption leading to contractile dysfunction by creating intercellular uncoupling through disrupting gap junction. This is supported by the results that artificial knockdown of CCRR reproduced conduction slowing and the associated arrhythmogenicity in healthy mice, which could be reversed by CCRR replacement. (3) On the contrary, overexpression of CCRR abrogates the conduction anomalies in the setting of HF, and CCRR was required for maintaining proper distribution of Cx43 in healthy mice, which could be reversed by CCRR replacement. (4) A sequence domain of CCRR that is conserved across species is responsible for CCRR:Cx43 interaction and the consequent disruption of CIP85:Cx43 interaction in the hearts of HF patients unraveled in this study. Our findings strongly indicate the critical involvement of IncRNAs in controlling cardiac electrophysiology, which should tremendously advance our understanding of the cellular functions and pathophysiological roles of IncRNAs. Yet, it should be mentioned that CCRR might also be able to act directly on the structural proteins of cardiomyocytes or other cells that are important to heart function and intercalated disc maintenance. Our study does not in any way exclude such a possibility that merits future studies to clarify.

Identification of CCRR loss-of-function as a new mechanism for the development of HF not only aids us to unravel the pathophysiological role of IncRNAs in cardiovascular disease, but also indicates a new approach that we could employ to handle the provoked arrhythmogenesis in the setting of HF. Our findings of the beneficial effects afforded by CCRR gain-of-function strongly suggest that CCRR replacement is a prospective therapeutic strategy for HF, particularly when considering the similar downregulation of CCRR and Cx43 and disruption of gap junction in the hearts of HF patients unraveled in this study. Our results indicated that a 290-nt fragment of CCRR was able to reproduce the beneficial actions of CCRR lends a further support to this view. Indeed, Cx43 dysfunction is a common mechanism for electrical disorders encountered in a variety of cardiovascular diseases including myocardial ischemia, cardiomyopathies, cardiac hypertrophy, atrial fibrillation, etc.5,8, in addition to HF, and improving cardiac gap junction communication has been considered a new antiarrhythmic mechanism.18–20 Nonetheless, extensive future studies are required to validate the potential of CCRR.

While IncRNAs are known to be associated with >150 human diseases, based on the annotations from the IncRNA and disease databases, their role in cardiovascular disease has just begun to be uncovered and the pertinent experimental studies have been rather scant. Here, we have presented an in-depth experimental
Fig. 7 Interactions between CCRR and CIP85 and between CIP85 and CX43. a RNA immunoprecipitation (RIP) showing the physical interaction between CCRR and CIP85 proteins in cultured neonatal mouse ventricular myocytes (NMVMs). Most left panel: the electrophoresis gel image showing the anticipated results of the electrophoretic bands. **P < 0.01 anti-CIP85 vs. anti-IgG; n = 4 batches of cells for each group. Middle left panel: the quantified results of the electrophoretic bands. **P < 0.01 anti-CIP85 vs. anti-IgG; n = 4 batches of cells for each group. Middle right panel: an example of immunoblotting bands showing the pulldown of CIP85 protein by CCRR or other RNAs as labeled on the left. ZFAS1: an lncRNA used as a negative control; AS: antisense to CCRR used as another negative control; AR: androgen receptor 3' UTR: a commercially obtained positive control; Input: purified CIP85 as a positive control; NC: negative control probe; HuR: Hu-antigen R. Right panel: mean relative band densities representing CIP85 protein with varying treatments. **P < 0.001 AS, ZFAS1, NC, vs. CCRR; n = 4. b Protein co-immunoprecipitation (Co-IP) confirming the physical interaction between CIP85 and CX43 in cultured NMVMs. Upper panel shows the presence of CIP85 in an anti-CX43 pulldown sample, and lower panel shows the presence of CX43 in an anti-CIP85 pulldown sample. c RIP results showing the physical interaction between FD and CIP85 proteins in healthy mice. Right panel: the quantified results of the electrophoretic bands. ***P < 0.01 anti-CIP85 vs. anti-IgG; n = 3 mice for each group. d Immunoblotting image showing the pulldown of CIP85 protein by FD. Sham: non-treated sample; Lv-FD: lentiviral vector carrying FD. Lv-FD-NC: lentiviral vector carrying negative sequence. Lower panel: mean relative band densities representing CIP85 protein with varying treatments. **P < 0.01 Lv-FD vs. Lv-FD-NC; n = 4. (Mean ± SEM; ANOVA followed by Dunnett’s test for multiple group comparisons, and Student t test for two group comparisons)

study on a specific lncRNA-CCRR in the setting of HF. This study characterized the role of CCRR downregulation in inducing arrhythmic phenotypes, defined intercellular uncoupling as a subcellular mechanism for the arrhythmogenesis, and deciphered backward trafficking as a signaling mechanism for reduced Cx43 protein in the plasma membrane in HF. These findings allowed us to draw up the following signaling pathway as a new mechanism for the long-recognized yet poorly understood arrhythmogenesis in HF: CCRR↓ → CIP85↑ → Cx43↓ → Gap junction↓ → Cardiac conduction↓ → Functional syncytium↓ → Arrhythmias↑ (Fig. 10).

Methods

Human preparations. We obtained the human cardiac tissues from the First Affiliated Hospital of the Harbin Medical University under the procedures approved by the Ethics Committee for Use of Human Samples of the Harbin Medical University (HMUIRB20160021), all human studies were performed in compliance with the relevant ethical regulations. The written informed consents were obtained from all subjects recruited to our study. The informed consents were obtained from every human subjects included in our study. The human ventricular endocardial tissue samples were collected from five HF patients diagnosed according to the NYHA (New York Heart Association) classification for the diagnosis and who had circulating NT-proBNP > 300 ng L⁻¹ or BNP > 100 ng L⁻¹ (Supplementary Table 1 for the clinical characteristics of the patients)²⁹. Tissues from three healthy human subjects were used as a control for HF samples. These subjects died of traffic accident and had voluntarily consented on the whole-body donation for medical research before accident.

Mouse model of pressure overload-induced congestive HF. C57BL/6 male mice weighing 22–26 g were obtained from the Liaoning Changle Biotechnology Co. Ltd. All procedures involving animals and their care were approved by the Institutional Animal Care and Use Committee of Harbin Medical University (No. HMUIRB-2008-06), all animal experiments were performed in compliance with the relevant ethical regulations. Animals were randomly divided into Sham-Control, HF model groups, and other groups as specified in the result descriptions. The pressure-overload HF was created by transverse aortic constriction (TAC) following the procedures described in our previous study¹⁶. In brief, an incision was made at the level of the suprasternal notch to allow direct access to transverse aortic. TAC was then performed by ligating the aorta between the right innominate artery and the left carotid artery over a 26-gauge blunt needle using 5-0 silk sutures for approximately 75% aortic constriction.

Eight weeks later, the animals received echocardiographic examinations. The mice with E/E' value lower than 50% cutoff were defined as HF. After 8 weeks, the mice were subjected to experimental interventions and measurements as specified in the data presentation. The animals were then sacrificed after anesthetized with 2,2,2-tribromoethanol (200 mg kg⁻¹, i.p.; Sigma, St. Louis, MO, USA), and their hearts were quickly excised and weighted in cold (4 °C) buffer. The left ventricle (LV) was then rapidly frozen in liquid nitrogen and stored at −80 °C for molecular experiments. In addition to the depressed cardiac contractile function, heart weight/body weight ratio and lung weight/body weight ratio were also measured to indicate the development of HF in our TAC model (Supplementary Figure 12). The investigator was blinded to the group allocation during the whole experimental procedures.

Mouse model of acute MI. C57BL/6 male mice weighing 22–26 g were anesthetized by intraperitoneally injected with 2% afoxil (100 mg kg⁻¹, i.p.; T48402; Sigma-Aldrich Corporation, St. Louis, MO, USA), and their chests were opened to expose the hearts. The left descending coronary artery (LAD) was ligated with a 7/0...
Echocardiographic analysis

Injection of 2,2,2-tribromoethanol (200 mg kg\(^{-1}\)) for two group comparisons.

Fig. 8 Effect of FD on gap junctional integrity. a Typical examples of electron microscopic images (30,000× magnification) showing the deranged intercalated discs in MI mice, and the effects of FD overexpression by Lv-FD on the microstructure of left ventricular cardiac muscles. Marked disruption of intercalated discs and gap junction was consistently observed in infarcted myocardium (dark arrows), and such derangement was ameliorated and restored to normal conditions after pretreatment with Lv-FD, but not with Lv-FD-NC. Similar observations were repeated in another three MI mice. b Effect of FD overexpression on the protein level of connexin43 (Cx43) in MI mice. Left panel: an example of Western blot bands; right panel: averaged data on Cx43 protein level. Cx43 expression was significantly repressed by MI and rescued by Lv-FD, relative to control and Lv-FD-NC, \( P < 0.05 \) MI or Lv-FC-NC vs. Sham; \( \#P < 0.05 \) Lv-FD vs. MI; \( n = 6 \) mice for each group. (Mean ± SEM; ANOVA followed by Dunnett’s test for multiple group comparisons, Student t test for two group comparisons).

Echocardiographic analysis. The mice were anesthetized by intraperitoneal injection of 2,2,2-tribromoethanol (200 mg kg\(^{-1}\); Sigma, St. Louis, MO, USA). They were then placed in the supine or lateral position on a warming pad. LV function was assessed by two-dimensional guided M-mode and transthoracic echocardiography with the echocardiographic system equipped with a 10.0-MHz phase-array transducer (Vevo2100, Visualsonics, Canada). Two-dimensional end-diastolic and end-systolic long-axis views of LV were standardized as follows: inclusion of the apex, the posterior papillary muscle, the mitral valve, and the aortic root. LV long-axis and short-axis papillary muscle level M-mode curves were recorded for measuring diastolic LV anterior wall, LV internal dimension at systole, thickness of diastolic LV posterior wall, thickness of systolic LV posterior wall, EF, and FS.

Determination of cardiac CV by optical mapping. Mice were heparinized and euthanized by perfusion with the electric-mechanical uncoupler Blebbistatin (50 nM ml\(^{-1}\); Sigma, St. Louis, MO, USA) followed by phenol/chloroform extraction. The heart was then isolated and Langendorff perfused with Henseleit solution (mM: NaCl 119, NaHCO\(_3\) 25, KCl 4, KH\(_2\)PO\(_4\) 1.2, MgCl\(_2\) 1, CaCl\(_2\) 1.8, glucose 10, and Na-pyruvate 2; pH adjusted to 7.4) bubbled with 95% O\(_2\)/5% CO\(_2\) (Liming Oxygen Company, Harbin, China)\(^{33}\). The heart was washed to clean up the blood and quickly mounted to the Langendorff perfusion apparatus. Two pairs of recording electrodes were fixed at the apex and base of the heart, respectively, and connected to the BL-420E\(^{29}\) integrated signal acquisition and processing system (Techman Software Company, Chengdu, China). Activations of cardiac muscles at the sites of apex and base were constantly recorded. The distance \( D \) between the two recording electrodes were measured and taken as the length of travel of excitation waves from apex to base. The appearance of the peaks of the second deflections within the activation complex on the surface electrocardiograms was set as the onset of cardiac activation at the recording site. The lag time \( \Delta T \) between cardiac activations at apex and base represents the time required for an excitation wave to travel the distance \( D \) between the two sites. The cardiac CV was then calculated according to the equation: \( CV = \Delta T / D \). For each data point of CV, 20 consecutive measurements were averaged from the 20 measurements. The CV measured in such a way represents the longitudinal conduction of the heart, which is presumably mediated by gap junction channels.

Assessment of propensity of ventricular arrhythmias. C57BL/6 mice were anesthetized with 2,2,2-tribromoethanol (200 mg kg\(^{-1}\); i.p.). An eight-electrode catheter (1.1F, Octapolar EP catheter; SciSense Inc., London, UK) was inserted through the jugular vein into the right ventricle of mice after anesthesia with the procedures essentially the same as detailed in our previous study\(^{34}\). Intracardiac pacing was performed through the catheter electrodes using an automated stimulator interfaced with the data acquisition system (GY6000; HeNaN HuAaN Medical Science & Technology Ltd., Zhengzhou, China), and ventricular activation was recorded directly from the surface recording electrode fixed on LV epicardium. Inducibility of VT was determined by applying a train of ten consecutive electrical pulses with a coupling interval of 80 ms (S1), followed by two extra stimuli (S2 and S3) at coupling intervals of 2 ms, respectively. Successful induction of VT was defined as the appearance of rapid nonsinus rhythm ventricular activations lasting for three beats or more.

RNA extraction. Total RNA was extracted from LV tissues from mice or human subjects using Trizol reagent according to the manufacturer’s instructions (Invitrogen, Camarillo, CA, USA) followed by phenol/chloroform extraction. The quality of the extracted RNA samples was confirmed by denaturing gel showing discrete 28 s and 5 s bands without smear.
**Fig. 9** Functional domain of CCRR (FD) improves gap junction communication. 

a Effects of conserved FD on gap junction communication assessed by dye transfer techniques in AC16 human adult ventricular cells (200× magnification). AC16 cells were loaded with a diffusible fluorescent dye (Lucifer yellow), and the diffusion of the dye was monitored under a laser confocal microscope. Note that transfection of pFD for FD overexpression significantly promoted, whereas pFD-Mut did not alter, the diffusion of Lucifer yellow among AC16 cells (green). The high molecular weight marker dye conjugate Rhodamine B was used as a negative control (red). Similar data were acquired from another three experiments.

b Effect of FD on the interaction between Cx43 and CIP85, as reported by co-immunoprecipitation in cultured NMVMs transfected with the plasmid carrying the FD (pFD) for overexpression. Note that the protein level of Cx43 co-immunoprecipitated by CIP85 antibody was significantly reduced. pFD-Mut: the mutant construct of pFD with nucleotide substitution to the putative binding site of CCRR or FD to CIP85.**

c Effect of CCRR or FD on the recruitment of Cx43 to lysosome and the presence of Cx43 in the plasma membrane determined by co-immunostaining of Cx43 and lysosome marker Lamp1 in cultured NMVMs (600× magnification). Note that either pCCRR or pFD weakened the overlapping staining of Cx43 and Lamp1, and enhanced the Cx43 staining to the cytoplasmic membrane. n = 3 batches of cells for each group. (Mean ± SEM; ANOVA followed by Dunnett’s test for multiple group comparisons, and Student t test for two group comparisons).

**Quantitative real-time RT-PCR (qPCR).** Complementary DNA synthesis was performed with random primer according to the manufacturer’s instructions (Reverse Transcription System, Promega; Cat#1202162). The SYBR Green PCR Master Mix Kit (Applied Biosystems; Cat#4309155) was used for real-time PCR to quantify the target genes on the ABI 7500 fast Real-Time PCR system (Applied Biosystems, USA). The specificity of the amplified product was monitored by its melting curve. PCR primers were designed using the Primer Premier 3.0 program (PREMIER Biosoft International, USA). Relative expressions of IncRNAs were calculated using the comparative cycle threshold (Ct) method (2^−ΔΔCt). Each data point was then normalized to GAPDH as an internal control in each sample. The final results are expressed as fold changes by normalizing the data to the values from control subjects.

**Isolation of neonatal mouse ventricular myocytes (NMVMs).** Cardiomyocytes were isolated from 1-day-old neonatal mice, neonatal mouse ventricles were cut into 1–2 mm³ after the hearts had been rapidly removed, and cells dissociated in 0.25% trypsin for 5 min. The collected tissue suspensions were then resuspended in DMEM (Biological Industries, Kibbutz Beit Haemek, Israel) supplemented with 10% fetal bovine serum (Biological Industries, Kibbutz Beit Haemek, Israel) and penicillin (100 U ml⁻¹)/streptomycin (100 μg ml⁻¹; Beyotime, Shanghai, China), and cultured at 37 °C in 5% CO₂ and 95% air in a humidified incubator. After 90 min for fibroblast adherence, the cell suspension was plated into 6-well plate at 3 × 10⁵ cells per well with DMEM. 5-bromo-2-deoxyuridine (10 nM) was added into the medium to remove fibroblasts.

**AC16 cell culture.** AC16 human adult ventricular cardiomyocyte cell line was a gift from Dr. Dongmei Zhang from Dalian Medical University. The cells were maintained in DMEM F-12 supplemented with 10% fetal bovine serum.

**Assessment of gap junction communication by the dye transfer method.** After varying treatments as specified in the main text, confluent AC16 human cardiomyocytes seeded on the coverslips were washed three times with 37 °C PBS. They were then plated into 35-mm dishes containing DMEM F-12 culture medium (Invitrogen Gibco, Carlsbad, CA, USA). Subsequently, 2 ml PBS containing the low molecular weight gap junction-permeable fluorescent dye Lucifer yellow (1%; Sigma, St. Louis, MA, USA) and the high molecular weight marker dye conjugate Rhodamine B dextran (1%; Sigma, St. Louis, MA, USA) was added to the center region of the coverslip. A 27-gauge needle was used to create longitudinal scratch across the cell monolayer. The cultures were rinsed with PBS 1 min following dye loading. The diffusion of the fluorescent dye was monitored under a laser confocal microscope and the distance of dye diffusion from the scratch margin was measured.

**Western blot analysis.** The total protein, surface membrane protein, and cytoplasmic protein samples were extracted from cardiac tissues of C57BL/6 mice or primary cultured cardiomyocytes for immunoblotting analysis. For the total protein analysis, frozen tissue was homogenized with 1000 μl solution containing 40% sodium dodecylsulfate (SDS), 60% RIPA and 1% protease inhibitor (Cat#539131; Millipore, MA, USA) in each 200 mg cardiac tissue. The homogenate was then centrifuged at 12,000 g for 30 min and the supernatants (containing cytosolic and membrane fractions) were collected. Extraction of surface and cytoplasmic proteins.
Immunohistochemistry. For mouse tissue, animals were anesthetized with 2,2,2-
trichloroethanol (200 mg·kg⁻¹, i.p.; Sigma, St. Louis, MO, USA), and the hearts
were quickly removed and perfused transcardially with 4% buffered PFA (pH 7.4).
For human cardiac tissues, the preparations were frozen and stored in liquid
nitrogen before use. The cardiac tissues were quickly removed and perfused transcardially with 4% buffered PFA (pH 7.4).

Nitrogen, Camarillo, CA, USA). The successful construction of the vector was veri-
cation and sequencing. The con-
ification and sequencing. The vector was identified after analyzing the plasmid sequence (inv-
trogen, Camarillo, CA, USA). The successful construction of the vector was verified by restriction enzyme digestion, PCR identification and sequencing. The con-
struction plasmid and lentivirus packaging plasmids plp1 and plp2 were co-transfected into the cultured HEK293T cells. Lentiviral particles were obtained by collecting supernatant using the kit for ultracentrifugation con-
centration and purification of lentiviral particles and combined with fluorescent
titer assay and ELISA. Virus titer was determined as 1 × 10⁶ transducing U ml⁻¹.
The viral constructs were administered into mouse heart by intracavity injection (injected into left ventricular chamber) after open heart surgery 1 week before TAC procedures.

Transfection of lncRNA siRNA and plasmids. LncRNA siRNA for CCRR (siCCRR) and a scrambled negative control RNA (siNC) were synthesized by Invitrogen (Carlsbad, CA, USA), and siRNA for CIP85 (siCIP85) by Shanghai Gene Pharma Co., Ltd. (Shanghai, China). These siRNAs were transfected at a final concentration of 100 nM or 2 μg plasmids (pCCRR, pFD, pFD-Mut) into NMVMs using the X-treme GENE Transfection Reagent (Roche, Indianapolis, USA) according to the manufacturer’s protocols.

CIP85-Cx43 co-immunoprecipitation. We followed essentially the procedures established by Cochrane et al. with minor modifications. Briefly, NMVMs were lysed in RIPA lysis buffer (50 mM Tris/pH 7.4, 150 mM NaCl, 1% sodium deoxycholate, 0.1% SDS, sodium orthovanadate, sodium fluoride, EDTA, leupeptin, and protease inhibitors) supplemented with protease inhibitors and the lysate was immunoprecipitated with a monoclonal Flag antibody (Sigma, USA) at 4 °C. As a negative control, an equal amount of the lysate was immunoprecipitated with a monoclonal GST antibody (Santa Cruz Biotechnology, CA, USA). The immune complexes were collected with protein A/G plus-agarose beads (Santa Cruz Biotechnology, CA) and washed ten times with PBS. Flag-CIP85 and Cx43 were detected by immunoblotting. The physical interaction between endogenous CIP85 and Cx43 was explored by precipitating with the CIP85 antibody or a polyclonal Flag antibody (Santa Cruz Biotechnology, CA, USA) as a negative control.

RI RNA immunoprecipitation. RNA immunoprecipitation was performed using the Magna RIP™ RNA-Binding Protein Immunoprecipitation Kit (Millipore, Darmstadt, Germany) according to manufacturer’s instructions, followed by real-time RT-PCR using the SYBR Green PCR Master Mix Kit (Applied Biosystems, Carlsbad, CA). RNAs were in vitro transcribed using the T7 RNA Polymerase Kit (Novagen, Madison, WI) and analyzed by RNA-PCR using primer pairs for the target genes and GAPDH. The PCR products were visualized by gel electrophoresis and quantified by densitometry.

Data analysis. Experimental data were expressed as mean ± SEM and they were analyzed with SPSS 24.0 software. Statistical comparisons among multiple groups were performed using analysis of variance (ANOVA) followed by Dunnett’s test. Student t test was carried out for comparisons between two groups. χ² test was used for nonparametric data set comparisons. A two-tailed P < 0.05 was taken to indicate a statistically significant difference. The sample size for whole animal experiments was set to be 5–6 mice for each group, and for molecular biology experiments, the sample size for set to 3–6 for each group and each data point was repeated in triplicate. The data on the animals died before the completion of the whole experimental procedures were excluded from our data analysis.

Code availability. No computer code was used to generate results for the current study.

Received: 11 October 2016 Accepted: 10 September 2018
Published online: 09 October 2018

References
1. Sano, T., Takayama, N. & Shimamoto, T. Directional difference of conduction velocity in the cardiac ventricular syncytium studied by microelectrodes. Circ. Res. 7, 262–267 (1959).

2. Dhein, S., Kräusemann, K. & Schafer, T. Effects of the gap junction uncoupler palmitoleic acid on the activation and repolarization wavefronts in isolated rabbit hearts. Br. J. Pharmacol. 120, 1375–1384 (1999).

3. Kostin, S. et al. Gap junction remodeling and altered connexin43 expression in the failing human heart. Mol. Cell. Biochem. 242(110), 135–144 (2003).

4. Peters, N. S., Green, C. R., Poole-Wilson, P. A. & Severs, N. J. Regulation of connexin43 gap junctions in ventricular myocardium from hypertrophied and ischemic human hearts. Circulation 88, 864–875 (1993).

5. Teunissen, B. E. J., Jongm, H. J. & Bierhuizen, M. F. A. Regulation of myocardial connexins during hypertrophic remodelling. Eur. Heart J. 25, 1979–1989 (2004).

6. Aleksandra, E. K., Philipp, M. G., Denise, P. B. & Florian, M. P. Gene regulation by the act of long-noncoding RNA transcription. BMC Biol. 11, 59 (2013).

7. Roberts, T. C., Morris, K. V. & Weinberg, M. S. Perspectives on the mechanism of transcriptional regulation by long-noncoding RNAs. Epigenetics 4, 304–305 (2014).

8. Scheuermann, J. C. & Boyer, L. A. Getting to the heart of the matter: long-noncoding RNAs in cardiac development and disease. EMBO J. 32, 1805–1816 (2013).

9. Regalla, K. & Thomas, T. Noncoding RNAs in cardiac remodeling and heart failure. Circ. Res. 113, 676–689 (2013).

10. Papait, R., Kunderfranco, P., Stipparo, G. G., Latronico, M. V. G. & Contorelli, G. Long Noncoding RNA: a new player of heart failure? J. Cardiovasc. Transl. Res. 6, 876–883 (2013).

11. Xinshu Grace, X., Marlin, T. & Yibin, W. Decoding the noncoding transcripts of heart failure. Circulation 129, 958–960 (2014).

12. Jae-Hyung, L. et al. Analysis of transcriptome complexity through RNA sequencing in normal and failing murine hearts. Circ. Res. 109, 1332–1341 (2011).

13. Li, D. et al. Transcriptome analysis reveals distinct patterns of long noncoding RNAs in heart and plasma of mice with heart failure. PLoS ONE 8, e77938–e77938 (2013).

14. Ka-Chien, Y. et al. Deep RNA sequencing reveals dynamic regulation of myocardial noncoding RNAs in failing human heart and remodeling with mechanical circulatory support. Circulation 129, 1009–1021 (2014).

15. Kun, W. et al. The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489. Circ. Res. 114, 1377–1388 (2014).

16. Liuhua, S. et al. Expression profile of long noncoding RNAs in a mouse model of cardiac hypertrophy. Int. J. Cardiol. 177, 73–75 (2014).

17. Peters, N. S., Green, C. R., Poole-Wilson, P. A. & Severs, N. J. Cardiac arrhythmogenesis and the gap junction. J. Mol. Cell. Cardiol. 27, 37–44 (1995).

18. Tribulova, N., Knezl, V. & Okhrulovich, L. J. Myocardial gap junctions: targets for novel approaches in the prevention of life-threatening cardiac arrhythmias. Physiol. Res. 57, 141–155 (2008).

19. Boafeng, Y. et al. The muscle-specific microRNA-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat. Med. 13, 486–491 (2007).

20. Saffitz, J. E., Schuessler, R. B. & Yamada, K. A. Mechanisms of remodeling of gap junction distribution and the development of anatomic substrates of arrhythmias. Cardiovasc. Res. 42, 309–317 (1999).

21. Giempan, B. N. Role of connexin43-interacting proteins at gap junctions. Adv. Cardiol. 42, 41–56 (2006).

22. Cochrane, K., Su, V. & Lau, A. F. The connexin43-interacting protein, CIP85, mediates the internalization of connexin43 from the plasma membrane. Cell Commun. Adhes. 20, 53–66 (2013).

23. Lan, Z., Kurata, W. E., Marty, K. J., Jin, C. & Lau, A. F. Novel rab GAP-like protein, CIP85, interacts with connexin43 and induces its degradation. Biochemistry 44, 2385–2396 (2005).

24. Kaprielian, R. R. et al. Downregulation of immunodetectable connexin43 and decreased gap junction size in the pathogenesis of chronic hibernation in the human left ventricle. Circulation 97, 651–660 (1998).

25. Saffitz, J. E. & Yamada, K. A. Do alterations in intercellular coupling play a role in cardiac contractile dysfunction? Circulation 97, 630–632 (1998).

26. Valencic, M. L. et al. Integrin activation in the heart: a link between electrical and contractile dysfunction? Circ. Res. 99, 1403–1410 (2006).

27. Gutstein, D. E. Heterogeneous expression of gap junction channels in the heart leads to conduction defects and ventricular dysfunction. Circulation 104, 1194–1199 (2001).

28. Chen, G. et al. LncRNA-disease: a database for long-noncoding RNA-associated diseases. Nucleic Acids Res. 41, D983–D986 (2013).

29. Neuhold, S. et al. Comparison of copetin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J. Am. Coll. Cardiol. 52, 266–272 (2008).

30. Tang, M. S., Redfors, B., Shao, Y. & Omerovic, E. Velocity vector imaging fails to quantify regional myocardial dysfunction in a mouse model of...
isoprenaline-induced cardiotoxicity. *Echocardiography* **29**, 818–826 (2012).

31. Aguilar, M., Xiong, F., Qi, X. Y., Comtois, P. & Nattel, S. Potassium channel blockade enhances atrial fibrillation-selective antiarrhythmic effects of optimized state-dependent sodium channel blockade. *Circulation* **132**, 2203–2211 (2015).

32. Yamada, C. et al. The renin-angiotensin system promotes arrhythmogenic substrates and lethal arrhythmias in mice with non-ischaemic cardiomyopathy. *Cardiovasc. Res.* **109**, 162–173 (2016).

33. Sabir, I. N., Fraser, J. A., Cass, T. R., Grace, A. A. & Huang, L. H. A quantitative analysis of the effect of cycle length on arrhythmogenicity in hypokalaemia. *Langendorff*-perfused murine hearts. *Pflüg. Arch.* **454**, 925–936 (2007).

34. Yasuno, S. et al. Angiotensin II type 1a receptor signalling directly contributes to the increased arrhythmogenicity in cardiac hypertrophy. *Br. J. Pharmacol.* **170**, 1384–1395 (2013).

Acknowledgments

This work was supported in part by the grants from the Funds for Creative Research Groups of the National Natural Science Foundation of China (81421063), National Key Research and Development Program of China (2017YFC1307403), the Key Project of National Science Foundation of China (81530010), and the Natural Science Foundation of China (81570357, 81570301, 81779284, 81773735, and 81673424).

Author contributions

L.H.S., Y.Z., L.N.X., H.L.S. and B.F.Y. designed, performed experiments, and supervised all aspects of the research and analyses. L.H.S., H.L.S. and B.F.Y. wrote and finalized the manuscript. L.H.S., Y.Z., L.N.X., Z.W.P., X.L.H., H.Q.R., J.Y.Z., L.J., L.N.C., X.X.W., T.T.Y., S.Q.W., Y.F., Y.G. and C.Y. participated in research, data analysis and interpretation. H.Y.L., Z.H.L. and W.X.M. were responsible for collecting heart tissue samples. Y.L.B., Y.Z., C.Q.X., Z.G.W., X.Y.Z. and Y.J.L. contributed to discussing, correcting, and finalizing the manuscript.

Additional information

Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-018-06637-9.

Competing interests: The authors declare no competing interests.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018